Epitope-Based Potential Vaccine Candidate for Humoral and Cell-Mediated Immunity to Combat Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic

dc.contributor.authorDas B.K.
dc.contributor.authorChakraborty D.
dc.date.accessioned2021-05-05T10:27:02Z
dc.date.available2021-05-05T10:27:02Z
dc.date.issued2020
dc.description.abstractThe emergence of severe acute respiratory syndrome from novel Coronavirus (SARS-CoV-2) has put an immense pressure worldwide where vaccination is believed to be an efficient way for developing hard immunity. Herein, we employ immunoinformatic tools to identify B-cell, T-cell epitopes associated with the spike protein of SARS-CoV-2, which is important for genome release. The results showed that the highly immunogenic epitopes located at the stalk part are mostly conserved compared to the receptor binding domain (RDB). Further, two vaccine candidates were computationally modeled from the linear B-cell, T-cell epitopes. Molecular docking reveals the crucial interactions of the vaccines with immune-receptors, and their stability is assessed by MD simulation studies. The chimeric vaccines showed remarkable binding affinity toward the immune cell receptors computed by the MM/PBSA method. van der Waals and electrostatic interactions are found to be the dominant factors for the stability of the complexes. The molecular-level interaction obtained from this study may provide deeper insight into the process of vaccine development against the pandemic of COVID-19. © 2020 American Chemical Society.en_US
dc.identifier.citationJournal of Physical Chemistry Letters Vol. 11 , 22 , p. 9920 - 9930en_US
dc.identifier.urihttps://doi.org/10.1021/acs.jpclett.0c02846
dc.identifier.urihttps://idr.nitk.ac.in/handle/123456789/15417
dc.titleEpitope-Based Potential Vaccine Candidate for Humoral and Cell-Mediated Immunity to Combat Severe Acute Respiratory Syndrome Coronavirus 2 Pandemicen_US
dc.typeArticleen_US

Files